低强度光疗的伞状综述：跨临床疾病的证据。
完整摘要 · 中文译文
低水平光疗法（LLLT）和光生物调节（PBM）已在多个临床领域得到研究。尽管已发表了大量系统评价，但其研究结果零散且不一致。本系统评价的伞形评价旨在综合LLLT在各种临床病症中的有效性和安全性的证据。检索了PubMed、Embase、Cochrane Library和Web of Science数据库，检索时间从建库至2026年2月24日。纳入的研究为关于人类LLLT的系统评价或荟萃分析。提取了关于临床病症、干预特征、结论总体方向及不良事件的数据。采用AMSTAR 2评估方法学质量。共纳入100篇系统评价，代表1，164次原始研究出现次数和790项唯一符合条件的原始研究。口腔和牙科病症构成了最大的证据基础（53篇评价），其次是肌肉骨骼疾病（22篇评价）、肿瘤相关并发症（8篇评价）以及伤口和淋巴病症（8篇评价）。总体而言，62篇评价得出的结论支持所评估的干预措施，34篇报告了中性或混合结论，4篇结论不明确。肿瘤相关并发症的有利结论比例最高。在100篇评价中，11篇报告了一项或多项不良事件或副作用，32篇明确报告无不良事件，57篇未提供不良事件信息。大多数评价的总体置信度评级为低（30.0%）或极低（60.0%），使用 根据AMSTAR 2评估，本综述文献提示低强度激光治疗（LLLT）在特定适应证中可能具有临床获益，尤其是肿瘤相关并发症如口腔黏膜炎。然而，这些描述性模式并不能确立治疗有效性或 underlying 证据的确定性。治疗参数的异质性、普遍较低的方法学置信度以及不良事件报告不完整限制了结果解读，并妨碍就安全性得出明确结论。
完整摘要 · 英文原文
Low-level light therapy (LLLT) and photobiomodulation (PBM) have been studied in diverse clinical fields. Although numerous systematic reviews have been published, their findings are fragmented and inconsistent. This umbrella review of systematic reviews aimed to synthesize the evidence on the effectiveness and safety of LLLT across various clinical conditions. PubMed, Embase, Cochrane Library, and Web of Science databases were searched from inception to February 24, 2026. Eligible studies were systematic reviews or meta-analyses of LLLT in humans. Data on clinical conditions, intervention characteristics, overall direction of conclusions, and adverse events were extracted. Methodological quality was assessed using AMSTAR 2. A total of 100 systematic reviews were included, representing 1,164 primary-study occurrences and 790 unique eligible primary studies. Oral and dental conditions accounted for the largest evidence base (53 reviews), followed by musculoskeletal disorders (22 reviews), oncology-related complications (8 reviews), and wound and lymphatic conditions (8 reviews). Overall, 62 reviews reached conclusions favoring the evaluated intervention, 34 reported neutral or mixed conclusions, and 4 had unclear conclusions. The highest proportion of favorable conclusions was observed for oncology-related complications. Of the 100 reviews, 11 reported one or more adverse events or side effects, 32 explicitly reported no adverse events, and 57 did not provide adverse-event information. Most reviews received low (30.0%) or critically low (60.0%) overall confidence ratings using AMSTAR 2. The review literature suggests potential clinical benefit of LLLT in selected indications, particularly oncology-related complications such as oral mucositis. However, these descriptive patterns do not establish treatment efficacy or the certainty of the underlying evidence. Heterogeneity in treatment parameters, generally low methodological confidence, and incomplete adverse-event reporting limit interpretation and preclude firm conclusions about safety.